Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study.
Feagan BG, Sandborn WJ, D'Haens G, Panés J, Kaser A, Ferrante M, Louis E, Franchimont D, Dewit O, Seidler U, Kim KJ, Neurath MF, Schreiber S, Scholl P, Pamulapati C, Lalovic B, Visvanathan S, Padula SJ, Herichova I, Soaita A, Hall DB, Böcher WO. Feagan BG, et al. Among authors: bocher wo. Lancet. 2017 Apr 29;389(10080):1699-1709. doi: 10.1016/S0140-6736(17)30570-6. Epub 2017 Apr 12. Lancet. 2017. PMID: 28411872 Free article. Clinical Trial.
Selective IL-23 Inhibition by Risankizumab Modulates the Molecular Profile in the Colon and Ileum of Patients With Active Crohn's Disease: Results From a Randomised Phase II Biopsy Sub-study.
Visvanathan S, Baum P, Salas A, Vinisko R, Schmid R, Grebe KM, Davis JW, Wallace K, Böcher WO, Padula SJ, Fine JS, Panés J. Visvanathan S, et al. Among authors: bocher wo. J Crohns Colitis. 2018 Nov 9;12(10):1170-1179. doi: 10.1093/ecco-jcc/jjy099. J Crohns Colitis. 2018. PMID: 30032288 Free PMC article. Clinical Trial.
Risankizumab in patients with moderate to severe Crohn's disease: an open-label extension study.
Feagan BG, Panés J, Ferrante M, Kaser A, D'Haens GR, Sandborn WJ, Louis E, Neurath MF, Franchimont D, Dewit O, Seidler U, Kim KJ, Selinger C, Padula SJ, Herichova I, Robinson AM, Wallace K, Zhao J, Minocha M, Othman AA, Soaita A, Visvanathan S, Hall DB, Böcher WO. Feagan BG, et al. Among authors: bocher wo. Lancet Gastroenterol Hepatol. 2018 Oct;3(10):671-680. doi: 10.1016/S2468-1253(18)30233-4. Epub 2018 Jul 25. Lancet Gastroenterol Hepatol. 2018. PMID: 30056030 Free article. Clinical Trial.
Fecal MicroRNAs Show Promise as Noninvasive Crohn's Disease Biomarkers.
Wohnhaas CT, Schmid R, Rolser M, Kaaru E, Langgartner D, Rieber K, Strobel B, Eisele C, Wiech F, Jakob I, Gantner F, Herichova I, Vinisko R, Böcher WO, Visvanathan S, Shen F, Panzenbeck M, Raymond E, Reber SO, Delić D, Baum P. Wohnhaas CT, et al. Among authors: bocher wo. Crohns Colitis 360. 2020 Jan;2(1):otaa003. doi: 10.1093/crocol/otaa003. Epub 2020 Feb 14. Crohns Colitis 360. 2020. PMID: 32551441 Free PMC article.
Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials.
Jensen DM, Asselah T, Dieterich D, Foster GR, Sulkowski MS, Zeuzem S, Mantry P, Yoshida EM, Moreno C, Ouzan D, Wright M, Morano LE, Buynak R, Bourlière M, Hassanein T, Nishiguchi S, Kao JH, Omata M, Paik SW, Wong DK, Tam E, Kaita K, Feinman SV, Stern JO, Scherer J, Quinson AM, Voss F, Gallivan JP, Böcher WO, Ferenci P. Jensen DM, et al. Among authors: bocher wo. Ann Hepatol. 2016 May-Jun;15(3):333-49. doi: 10.5604/16652681.1198803. Ann Hepatol. 2016. PMID: 27049487 Free article.
ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection.
Asselah T, Zeuzem S, Soriano V, Bronowicki JP, Lohse AW, Müllhaupt B, Schuchmann M, Bourlière M, Buti M, Roberts SK, Gane EJ, Stern JO, Voss F, Baum P, Gallivan JP, Böcher WO, Mensa FJ. Asselah T, et al. Among authors: bocher wo. PLoS One. 2015 Dec 9;10(12):e0144004. doi: 10.1371/journal.pone.0144004. eCollection 2015. PLoS One. 2015. PMID: 26650626 Free PMC article. Clinical Trial.
Mechanisms underlying benign and reversible unconjugated hyperbilirubinemia observed with faldaprevir administration in hepatitis C virus patients.
Sane RS, Steinmann GG, Huang Q, Li Y, Podila L, Mease K, Olson S, Taub ME, Stern JO, Nehmiz G, Böcher WO, Asselah T, Tweedie D. Sane RS, et al. Among authors: bocher wo. J Pharmacol Exp Ther. 2014 Nov;351(2):403-12. doi: 10.1124/jpet.114.218081. Epub 2014 Sep 9. J Pharmacol Exp Ther. 2014. PMID: 25204339 Clinical Trial.
Restoration of HCV-specific CD8+ T cell function by interferon-free therapy.
Martin B, Hennecke N, Lohmann V, Kayser A, Neumann-Haefelin C, Kukolj G, Böcher WO, Thimme R. Martin B, et al. Among authors: bocher wo. J Hepatol. 2014 Sep;61(3):538-43. doi: 10.1016/j.jhep.2014.05.043. Epub 2014 Jun 4. J Hepatol. 2014. PMID: 24905492 Clinical Trial.
SILEN-C3, a phase 2 randomized trial with faldaprevir plus pegylated interferon α-2a and ribavirin in treatment-naive hepatitis C virus genotype 1-infected patients.
Dieterich D, Asselah T, Guyader D, Berg T, Schuchmann M, Mauss S, Ratziu V, Ferenci P, Larrey D, Maieron A, Stern JO, Ozan M, Datsenko Y, Böcher WO, Steinmann G. Dieterich D, et al. Among authors: bocher wo. Antimicrob Agents Chemother. 2014 Jun;58(6):3429-36. doi: 10.1128/AAC.02497-13. Epub 2014 Apr 7. Antimicrob Agents Chemother. 2014. PMID: 24709256 Free PMC article. Clinical Trial.
Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir.
Berger KL, Triki I, Cartier M, Marquis M, Massariol MJ, Böcher WO, Datsenko Y, Steinmann G, Scherer J, Stern JO, Kukolj G. Berger KL, et al. Among authors: bocher wo. Antimicrob Agents Chemother. 2014;58(2):698-705. doi: 10.1128/AAC.01976-13. Epub 2013 Nov 11. Antimicrob Agents Chemother. 2014. PMID: 24217701 Free PMC article.
42 results